Pharvaris N.V. (NASDAQ:PHVS) Short Interest Up 43.7% in December

Pharvaris N.V. (NASDAQ:PHVS) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 636,914 shares, an increase of 43.7% from the November 30th total of 443,097 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 653,889 shares, the short-interest ratio is currently 1.0 days. Based on an average daily trading volume, of 653,889 shares, the short-interest ratio is currently 1.0 days. Currently, 1.2% of the shares of the stock are sold short.

Pharvaris Stock Up 5.7%

PHVS stock traded up $1.50 during mid-day trading on Wednesday, hitting $27.75. 427,021 shares of the company were exchanged, compared to its average volume of 157,945. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.80. The firm has a market capitalization of $1.45 billion, a P/E ratio of -8.64 and a beta of -2.80. The business has a fifty day simple moving average of $24.56 and a 200-day simple moving average of $22.65.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.08. Research analysts predict that Pharvaris will post -2.71 EPS for the current year.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently modified their holdings of PHVS. Wellington Management Group LLP purchased a new stake in shares of Pharvaris in the 3rd quarter valued at $43,282,000. Paradigm Biocapital Advisors LP grew its position in Pharvaris by 72.7% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after acquiring an additional 772,583 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in Pharvaris during the third quarter worth about $15,613,000. Commodore Capital LP lifted its position in shares of Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after purchasing an additional 507,043 shares in the last quarter. Finally, General Atlantic L.P. boosted its stake in shares of Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after purchasing an additional 500,000 shares during the period.

Wall Street Analyst Weigh In

PHVS has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th. Wall Street Zen lowered Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Bank of America increased their price target on Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Thursday, December 4th. Guggenheim boosted their price objective on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Oppenheimer upped their target price on Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Pharvaris has an average rating of “Moderate Buy” and an average price target of $40.56.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.